Northwest Biotherapeutics, Inc. (NWBO)
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
$384.46M
Ms. Linda F. Powers J.D.
19.00
Bethesda, MD
Dec 14, 2001
-4.40
$-0.07
0.05
0.09
-4,510.58%
-5.07
-1.48
-6.53
235.23
0.09
-262.15%
133.00%
Similar stocks (4)
Celldex Therapeutics, Inc.
CLDX
CEL-SCI Corporation
CVM
EOM Pharmaceuticals Holdings, Inc.
IMUC
Advaxis, Inc.
ADXS
Similar stocks (4)
Celldex Therapeutics, Inc.
CLDX
CEL-SCI Corporation
CVM
EOM Pharmaceuticals Holdings, Inc.
IMUC
Advaxis, Inc.
ADXS